Carles Arus
Overview
Explore the profile of Carles Arus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
794
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ungan G, Pons-Escoda A, Ulinic D, Arus C, Ortega-Martorell S, Olier I, et al.
NMR Biomed
. 2024 Jan;
37(4):e5095.
PMID: 38213096
The standard treatment in glioblastoma includes maximal safe resection followed by concomitant radiotherapy plus chemotherapy and adjuvant temozolomide. The first follow-up study to evaluate treatment response is performed 1 month...
2.
Zhao K, Calero-Perez P, Bopp M, Moschl V, Pagenstecher A, Mulero-Acevedo M, et al.
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139457
The tumor microenvironment in glioblastoma (GB) is considered to be "cold", i.e., the fraction of cytotoxic T cells, for instance, is low. Instead, macrophages are the major immune cell population...
3.
Ungan G, Arus C, Vellido A, Julia-Sape M
NMR Biomed
. 2023 Aug;
36(12):e5020.
PMID: 37582395
Magnetic resonance spectroscopy (MRS) is an MR technique that provides information about the biochemistry of tissues in a noninvasive way. MRS has been widely used for the study of brain...
4.
Ungan G, Pons-Escoda A, Ulinic D, Arus C, Vellido A, Julia-Sape M
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509372
Purpose: To test whether MV grids can be classified with models trained with SV. Methods: Retrospective study. Training dataset: Multicenter multiformat SV INTERPRET, 1.5T. Testing dataset: MV eTumour, 3T. Two...
5.
Alfonso-Triguero P, Lorenzo J, Candiota A, Arus C, Ruiz-Molina D, Novio F
Nanomaterials (Basel)
. 2023 May;
13(10).
PMID: 37242036
Current therapies for treating Glioblastoma (GB), and brain tumours in general, are inefficient and represent numerous challenges. In addition to surgical resection, chemotherapy and radiotherapy are presently used as standards...
6.
Candiota A, Arus C
Metabolites
. 2022 Mar;
12(3).
PMID: 35323686
This hypothesis proposal addresses three major questions: (1) Why do we need imaging biomarkers for assessing the efficacy of immune system participation in glioblastoma therapy response? (2) Why are they...
7.
Calero-Perez P, Wu S, Arus C, Candiota A
Cancers (Basel)
. 2021 Jun;
13(11).
PMID: 34071393
Glioblastomas (GB) are brain tumours with poor prognosis even after aggressive therapy. Previous work suggests that magnetic resonance spectroscopic imaging (MRSI) could act as a biomarker of efficient immune system...
8.
Villamanan L, Martinez-Escardo L, Arus C, Yuste V, Candiota A
Int J Mol Sci
. 2021 Apr;
22(7).
PMID: 33810611
Background: The relevance of the cancer immune cycle in therapy response implies that successful treatment may trigger the exposure or the release of immunogenic signals. Previous results with the preclinical...
9.
Wu S, Calero-Perez P, Arus C, Candiota A
Int J Mol Sci
. 2020 Nov;
21(22).
PMID: 33233585
Glioblastomas (GBs) are malignant brain tumours with poor prognosis even after aggressive therapy. Programmed cell death-1 (PD-1) immune checkpoint blockade is a promising strategy in many types of cancer, but...
10.
Nunez L, Romero E, Julia-Sape M, Ledesma-Carbayo M, Santos A, Arus C, et al.
Sci Rep
. 2020 Nov;
10(1):19699.
PMID: 33184423
Glioblastoma is the most frequent aggressive primary brain tumor amongst human adults. Its standard treatment involves chemotherapy, for which the drug temozolomide is a common choice. These are heterogeneous and...